Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study

Costa, Pedro Fragoso; Jentzen, Walter; SÜßELBECK, Finja; Fendler, Wolfgang P.; Rischpler, Christoph; Herrmann, Ken; Conti, Maurizio; Kersting, David; Weber, Manuel

doi:10.23736/s1824-4785.21.03300-8

Cited by 10 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor and organ absorbed doses were calculated by integration of a mono-exponential fit function over time. We assumed that the radionuclide content on liver and lung would be equal to the minimum quantifiable 90 Y-FAPI-46 uptake in PET phantom studies ( 17 ) and applied the blood pharmacokinetics for calculation of the absorbed doses.…”

Section: Methodsmentioning

confidence: 99%

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Fendler

Pabst

Kessler

et al. 2022

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: We report efficacy and safety of 90Y-FAPI-46-RLT in patients with advanced sarcoma, pancreatic cancer (PDAC) and other cancer entities. Experimental Design: Up to four cycles of RLT were offered to patients with (a) progressive metastatic malignancy, (b) exhaustion of approved therapies, and (c) high fibroblast activation protein (FAP) expression, defined as SUVmax≥10 in more than 50% of tumor. Primary endpoint was RECIST response after RLT. Secondary endpoints included PET response (PERCIST), overall survival, dosimetry and safety of FAP-RLT. Results: Among n=119 screened patients, n=21 (18%) were found eligible (n=16/3/1/1 sarcoma/PDAC/prostate/gastric cancer; 38% ECOG≥2) and received n=47 90Y-FAPI-46-RLT cycles; n=16/21 (76%) patients underwent repeat RLT. By RECIST disease control was confirmed in n=8/21 patients (38%; 8/16 [50%] of evaluable patients). There were 1 partial response and 7 stable diseases after RLT. Disease control was associated with prolonged overall survival (p=0.013). PERCIST response was noted in n=8/21 patients (38%; 8/15 [53%] of evaluable patients). Dosimetry was acquired in n=19 (90%) patients. Mean absorbed dose was 0.53Gy/GBq in kidney, 0.04Gy/GBq in bone marrow and <0.14Gy/GBq in liver and lung. Treatment-related grade 3 or 4 adverse events were observed in n=8 (38%) patients with thrombocytopenia (n=6) and anemia (n=6) being most prevalent. Conclusion: 90Y-FAPI-46-RLT was safe and led to RECIST partial response in one case as well as stable disease in about one third of patients with initially progressive sarcomas, PDAC and other cancers. Discontinuation after the first cycle and a low rate of partial response require for future improvement of FAP-RLT.

show abstract

Section: Methodsmentioning

confidence: 99%

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Fendler

Pabst

Kessler

et al. 2022

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Bone–lung phantom was composed of 3 different cylinders (each with a diameter of 50 mm) made of different materials (lung with -800 HU, bone with 500 HU, and 1000 HU) that are housed within the standard NEMA IQ phantom [ 24 ]. Within every cold cylinder, two fillable spheres were inserted, one with a diameter of 8.5 mm and one with 19.4 mm.…”

Section: Methodsmentioning

confidence: 99%

Positron range in combination with point-spread-function correction: an evaluation of different implementations for [124I]-PET imaging

et al. 2022

Self Cite

View full text Add to dashboard Cite

Aim To evaluate the effect of combining positron range correction (PRC) with point-spread-function (PSF) correction and to compare different methods of implementation into iterative image reconstruction for 124I-PET imaging. Materials and methods Uniform PR blurring kernels of 124I were generated using the GATE (GEANT4) framework in various material environments (lung, water, and bone) and matched to a 3D matrix. The kernels size was set to 11 × 11 × 11 based on the maximum PR in water and the voxel size of the PET system. PET image reconstruction was performed using the standard OSEM algorithm, OSEM with PRC implemented before the forward projection (OSEM+PRC simplified) and OSEM with PRC implemented in both forward- and back-projection steps (full implementation) (OSEM+PRC). Reconstructions were repeated with resolution recovery, point-spread function (PSF) included. The methods and kernel variation were validated using different phantoms filled with 124I acquired on a Siemens mCT PET/CT system. The data was evaluated for contrast recovery and image noise. Results Contrast recovery improved by 2–10% and 4–37% with OSEM+PRC simplified and OSEM+PRC, respectively, depending on the sphere size of the NEMA IQ phantom. Including PSF in the reconstructions further improved contrast by 4–19% and 3–16% with the PSF+PRC simplified and PSF+PRC, respectively. The benefit of PRC was more pronounced within low-density material. OSEM-PRC and OSEM-PSF as well as OSEM-PSF+PRC in its full- and simplified implementation showed comparable noise and convergence. OSEM-PRC simplified showed comparably faster convergence but at the cost of increased image noise. Conclusions The combination of the PSF and PRC leads to increased contrast recovery with reduced image noise compared to stand-alone PSF or PRC reconstruction. For OSEM-PRC reconstructions, a full implementation in the reconstruction is necessary to handle image noise. For the combination of PRC with PSF, a simplified PRC implementation can be used to reduce reconstruction times.

show abstract

“…These systems use silicon photomultiplier-based detectors leading to an improved spatial and coincidence timing resolution and reduced image noise [ 180 , 181 , 182 , 183 , 184 , 185 ]. Possible clinical benefits include a reduction in administered activity or acquisition time [ 186 , 187 , 188 , 189 , 190 ] leading to increased patient comfort, particularly regarding pain-stricken or dyspneic patients [ 191 ] from which symptomatic patients with cardiotoxicity might also benefit. In addition, digital PET improves the detectability, especially of small structures and those with low tracer-uptake [ 182 , 192 , 193 , 194 ], which may facilitate the visualization of new biomarkers.…”

Section: Future Trendsmentioning

confidence: 99%

Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology

Kersting

Settelmeier

Mavroeidi

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

The emerging use of immunotherapies in cancer treatment increases the risk of immunotherapy-related cardiotoxicity. In contrast to conventional chemotherapy, these novel therapies have expanded the forms and presentations of cardiovascular damage to a broad spectrum from asymptomatic changes to fulminant short- and long-term complications in terms of cardiomyopathy, arrythmia, and vascular disease. In cancer patients and, particularly, cancer patients undergoing (immune-)therapy, cardio-oncological monitoring is a complex interplay between pretherapeutic risk assessment, identification of impending cardiotoxicity, and post-therapeutic surveillance. For these purposes, the cardio-oncologist can revert to a broad spectrum of nuclear cardiological diagnostic workup. The most promising commonly used nuclear medicine imaging techniques in relation to immunotherapy will be discussed in this review article with a special focus on the continuous development of highly specific molecular markers and steadily improving methods of image generation. The review closes with an outlook on possible new developments of molecular imaging and advanced image evaluation techniques in this exciting and increasingly growing field of immunotherapy-related cardiotoxicity.

show abstract

Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study

Cited by 10 publications

References 38 publications

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Positron range in combination with point-spread-function correction: an evaluation of different implementations for [124I]-PET imaging

Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology

Contact Info

Product

Resources

About